Grupo Biotoscana expands its partnership with Gilead Sciences

Grupo Biotoscana expands its partnership with Gilead Sciences in HCV in Brazil. The new agreement extends the term for SOVALDI® and now also includes HARVONI®

GBT-Grupo Biotoscana (B3: GBIO33), a leading specialty pharmaceutical company in Latin America, today announced that it has expanded its partnership with Gilead Sciences (Nasdaq: GILD) in HCV in Brazil. Under a previous agreement, Gilead Sciences had granted distribution rights to GBT-Grupo Biotoscana (GBT), for SOVALDI® (400 mg sofosbuvir). Under the new agreement, the parties have arranged to extend the term for SOVALDI® and include the distribution of HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir). GBT maintains all its rights and obligations under prior agreement. This announcement confirms the intensification of the years-long partnership between GBT and Gilead Sciences.

GBT is very enthusiastic to be able to expand this existing partnership and broaden the HCV treatment options by adding leading brand HARVONI® to better serve more patients and doctors with this serious infectious disease, explains Mariano García-Valiño, CEO of GBT.

HARVONI® is not an approved drug in Brazil yet, where local health authorities are in the process of reviewing the health registration dossier filed by Gilead Sciences.

Gilead Sciences will continue to be responsible for supplying these treatment options directly to the Brazilian Ministry of Health.

See the full article.

About GBT
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products.

To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com

About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com

About SOVALDI®
SOVALDI® (400 mg sofosbuvir). is a prescription medicine used with other antiviral medicines to treat chronic (lasting a long time) hepatitis C genotype 1, 2, 3, or 4 infections in adults. It is not known if SOVALDI® is safe and effective in children under 18 years of age. Brazil full prescribing information for SOVALDI® is available here.

About HARVONI®
HARVONI® (90 mg ledipasvir / 400 mg sofosbuvir) is a prescription medicine used with or without ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1, 4, 5 or 6 infections. It is not known if HARVONI® is safe and effective in children under 18 years of age. HARVONI® is under review of Brazilian health authorities and it is not yet an approved drug in this territory.
SOVALDI® and HARVONI® are registered trademarks of Gilead Sciences, Inc. or its related companies.

Forward-Looking Statements (GBT)

This release includes forward-looking statements concerning a transaction between Gilead Sciences and GBT-Grupo Biotoscana, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.